Mortality and survival in a cohort of 1,115 HIV-infected patients (1989-97);Estudio de la mortalidad y supervivencia en una cohorte de 1.115 pacientes con infección VIH (1989-97)

Anales de Medicina Interna

Volumn 21, Issue 11, 2004, Pages 523-532

  San Andres Rebollo F J ^a,e   Rubio Garcia R ^b   Castilla Catalan J ^c   Pulido Ortega, F ^b   Palao, G ^b   De Pedro Andres I ^d   Costa Perez Herrero J R ^b   Del Palacio Perez Medel A ^b  

^a MEDICINA FAMILIAR Y COMUNITARIA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c CARLOS III INSTITUTE OF HEALTH   (Spain)

^d Residente de Medicina Familiar Y Comunitaria   (Mexico)

^e NONE   (Mexico)

Author keywords

Adherence; Compliant; Mortality; Survivival; Trend

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE;

ADOLESCENT; ADULT; AGED; ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 10944236840     PISSN: 02127199     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Hoover DR. The effects of long-term zidovudine therapy and Pneumocystis carinii prophylaxis on HIV disease: a review of the literature. Drugs 1995; 49: 20-36.
2. Lemp GF, Payne SF, Neal D, Temelso T, Rutherford GW. Survival trends for patients with AIDS. JAMA 1990; 263: 402-406.
3. Osmond D, Charlebois E, Lang W, Shiboski S, Moss A. Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. JAMA 1994; 271: 1.083-1.087.
4. Jacobson LP, Kirby AJ, Polk S, et al. Changes in survival after Acquired Immunodeficiency Syndrome (AIDS): 1984-1991. Am J Epidemiol 1993; 138: 952-964.
5. Blum S, Singh TP, Gibbons J, et al. Trends in survival among persons with Acquired Immunodeficiency Syndrome in New York City: the experience of first decade of the epidemic. Am J Epidemiol 1994; 139: 351-361.
6. Buira E, Gatell JM, Zamora L, Nallolas J, Miró JM, Soriano E. Análisis de 1.187 casos consecutivos de sida: variaciones y tendencias en el tiempo. Enferm Infecc Microbiol Clin 1996; 14: 290-295.
7. Mocroft A, Youle M, Morcineck J, et al, for the Royal Free/Chelsea and Westminster Hospitals Colaborative Group. Survival after diagnosis of AIDS: a prospective observational study of 2.625 patients. BMJ 1997; 314: 409-413.
8. Graham NMH, Zeger SL, Park LP, et al. The effects on survival of early treatment of Human Immunodeficiency Virus infection. N Engl J Med 1992; 326: 1.037-1.042.
9. Chaisson RE, Keruly J, Richman DD, Moore RD, for the Zidovudine Epidemiology Group. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. Arch Intern Med 1992; 152: 2.009-2.013.
10. Palella FJ, Delaney KM, Moorman AC, et al, and the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860.
11. Detels R, Muñoz A, McFarlane G, et al, for the Multicenter AIDS Cohort Study investigators. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998; 280: 1.497-1.503.
12. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999; 179: 717-720.
13. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279: 450-454.
14. Moore RD, Keruly J, Richman DD, Creagh-Kirk T, Chaisson RE. Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group. AIDS 1992; 6: 671-677.
15. McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW, and the Adult/Adolescent Spectrum od Disease Group. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. AIDS 1999; 13: 1.687-1.695.
16. European Centre for the Epidemiological Monitoring of AIDS. HIV/AIDS surveillance in Europe. End-year report 2000, n° 65. 2001.
17. Valero JA, Ruiz-Navarro MD. Evolución de la supervivencia del sida en España: efecto de la inclusión de la tuberculosis pulmonar en la definición de caso en la era de los inhibidores de la proteasa. Rev Clin Esp 1998; 198: 526-528.
18. Mocroft AJ, Lundgren JD, Monforte AD, et al, for the AIDS in Europe Study Group. Survival of AIDS patients according to type of AIDS-definig event. Int J Epidemiol 1997; 28: 400-407.
19. Gil V, Pineda M, Martínez JL, Belda J, Santos ML, Merino J. Validez de 6 métodos indirectos para valorar el cumplimiento terapeútico en hipertensión arterial. Med Clin (Barc) 1994; 102: 532-536.
20. Abraira V, Pérez de Vargas A. Regresión de Poisson. En: Abraira V, Pérez de Vargas A, editores. Métodos multivariantes en bioestadística. Madrid: Centro de Estudios Ramón Areces; 1996. p. 263-281.
21. Kleinbaum DG. Extension of the Cox Proportional Hazards Model for Time-Dependent Variables. En: Dietz k, Gail M, Krickerberg K, Singer B, editores. Survival analysis: A self-learning text. New York: Springer-Verlag; 1997. p. 211-253.
22. Castillla J, De la Fuente, L. Evolución del numéro de personas infectadas por el VIH y de los casos de sida. España: 1980-1998. Med Clin(Barc) 2000; 115: 85-89.
23. Centre Européen pour la Surveillance Epidémiologique du Sida. Surveillance du VIH/sida en Europe: Rapport n° 61, 30 juin 1999.
24. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999; 13: 1.933-1.942.
25. Egger M, Hirschel B, Francioli P, et al, and the Swiss HIV Cohort Study. Impact of new antiretroviral combination therapies in HIV infected patients in Swizerland: prospective multicentre study. BMJ 1997; 315: 1.194-1.199.
26. Rothenberg R, Woelfel M, Stoneburner R, Milberg J, Parker R, Truman B. Survival with the Acquired Immunodeficiency Syndrome: experience with 5.833 cases in New York City. N Engl J Med 1987; 317: 1.297-1.302.
27. Caylà JA, Artazcoz L, Iglesias B, Jansà JM, Plasència A. Epidemiología del sindrome de inmunodeficiencia adquirida en Barcelona (1981-1991) (II). Estudio de mortalidad y de supervivencia. Med Clin (Barc) 1994; 102: 129-135.
28. García de Olalla P, Caylà JA, Brugal MT, Galdós H, Jansá JM, Clos R. Evolución de la mortalidad y supervivencia del sida en Barcelona (1981-1997). Med Clin (Barc) 1999; 113: 169-170.
29. Schwarcz SK, Chin L, Vittinghoff E, Katz MH. Impact of protease inhibitors and other antiretroviral treatments on Acquired Immunodeficiency Syndrome survival in San Francisco, California; 1987-1996. Am J Epidemiol 2000; 152: 178-185.
30. Lee LM, Karon JM, Selik R, Neal J, Fleming PL. Survival after AIDS diagnosis in Adolescents and Adults during the Treatment era, United States, 1984-1997. JAMA 2001; 285: 1308-1315.
31. Miralles R, Garcés JM, Gallén M, et al. Síndrome de inmunodeficeincia adquirida: estudio descriptivo y análisis de la supervivencia en 73 casos. Med Clin (Barc) 1990; 94: 401-405.
32. Lundgren JD, Barton SE, Katlama C, et al, for the Multicenter Study Group on AIDS in Europe. Changes in survival over time after a first episode on Pneumocystis carinii for european patients with Acquired Immunodeficiency Syndrome. Arch Intern Med 1995; 155: 822-828.
33. Rubio R, Pulido F, Pintado V, et al. Linfomas no hodgkinianos asociados al síndrome de la inmunodeficiencia adquirida. Estudio clínico multicéntrico de 77 casos. Grupo Cooperativo sida y Tumores de Madrid. Med Clin (Barc) 1995; 104: 481-486.
34. Casabona J, Salas T, Salinas R. Trends and survival in AIDS-associated malignancies. Eur J Cancer 1993; 294: 877-881.
35. Conti S, Masocco M, Pezzotti P, et al. Differential impact of combined antiretroviral therapy on the survival of italian patients with specific AIDS-defining illnesses. J Acquir Immune Defic Syndr 200; 25: 451-458.
36. Luo K, Law M, Kaldor JM, McDonald, Cooper D. The role of initial AIDS-defining illness in survival following AIDS. AIDS 1995; 9: 57-63.
37. Herrero JA, Sánchez MD, Palenque E, et al. Infección diseminada por Mycobacterium avium-intracellulare en pacientes con sida. Med Clin (Barc) 1993; 100: 171-173.
38. Low N, Pfluger D, Egger M, and the Swiss HIV Cohort Study. Disseminated Mycobacterium avium complex disease in the Swiss HIV Cohort Study: increasing incidence, unchanged prognosis. AIDS 1997; 11: 1.165-1.171.
39. Oksenhendler E, Carreau I, Tournerie C, Azihary M, Carbon C, Aboulker JP. Toxoplasma gondii infection in advanced HIV infection. AIDS 1994; 8: 483-487.
40. Gallant JE, Moor RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis 1992; 166: 1.223-1.227.
41. Petruckevitch A, Del Amo J, Phillips AN, et al. Disease progression and survival following specific AIDS-defining conditions: a retrospective cohort study of 2.048 HIV-infected persons in London. AIDS 1998; 12: 1.007-1.013.
42. Chaisson RE, Gallant JE, Keruly JC, Moore RD. Impact of opportunistic disease on survival in patients with HIV infection. AIDS 1998; 12: 29-33.
43. Casari S, Donisi A, Paraninfo G, et al. Pronostic factors correlated with survival in AIDS patients. Eur J Epidemiol 1999; 15: 691-698.
44. Sha BE, Benson CA, Pottage JC, Urbanski PA, Daugherty SR, Kessler HA. HIV infection in woman: an observational study of clinical characteristics, disease progression, and survival for a cohort of woman in Chicago. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 486-495.
45. Mocroft A, Johnson MA, Phillips AN. Factors affecting survival in patients with the acquired immunodeficiency syndrome. AIDS 1996; 10: 1.057-1.065.
46. Prins M, Veugelers PJ, for the European Seroconverter Study and Tricontinental Seroconverter Study. Comparison of progression and non-progression in injecting druf users and homosexual men with documented dates of HIV-1 seroconversion. AIDS 1997; 11: 621-631.
47. Gatell JM, González-Lahoz J, Clotet B, et al, and the ddI Iberian Study Group. Switching from zidovudine to didanosine in patients with symptomatic HIV infection no disease progression. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12: 249-258.
48. Fischl MA, Stanley K, Collier AC, et al, and the NIAID AIDS Trials Group. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995; 122: 24-32.
49. Lundgren JD, Phillips AN, Pedersen C, et al, for the AIDS in Europe Study Group. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. JAMA 1994; 271: 1.088-1.092.
50. Buira E, Gatell JM, Miró JM, et al. Influence of treatment with zidovudine (ZDV) on the long-term survival of AIDS patients. J Acquir Immune Defic Syndr 1992; 5: 737-742.
51. Pezzotti P, Napoli PA, Acciani S, et al. Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies. AIDS 1999; 13: 249-255.
52. Hamilton JD, Hartigan PM, Simberkoff MS, et al, and the Veterans Affairs Cooperative Study Group on AIDS Treatment. A controlled trial of early versus late treatment with zidovudine in symptomatic Human Immunodeficiency Virus infection. N Eng J Med 1992; 326: 437-443.
53. Gálvez C, Blanco F, del Amo J, Ruiz-Navarro MD, Soriano V, González J. Efecto del tratamiento antirretrovírico y de la profilaxis para enfermedades oportunistas en la supervivencia de los pacientes con sida. Rev Clin Esp 2000; 200: 187-192.
54. Graham NMH, Hoover DR, Park LP, et al, for the Multicenter AIDS Cohort Study Group. Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine mootherapy. Ann Intern Med 1996; 124: 1.031-1.038.
55. Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the Acquired Immunodeficiency Syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996; 335: 1.099-1.106.
56. Hammer SM, Katzenstein DA, Hughes MD, et al, for the AIDS Clinical Trials Group Study 175. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335: 1.081-1.090.
57. Phillips AN, Katlama C, Barton S, et al. for the Euro-sida Study Group. Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. J Acquir Immune Defic Syndr 1998; 17: 239-244.
58. Knobel H, Serrano C, Hernández P, Pavesi M, Díez A. Aceptación, cumplimiento y tolerancia del tratamiento antirretroviral en pacientes con infeccion por el virus de la inmunodeficiencia humana. An Med Interna (Madrid) 1997; 14: 445-449.
59. Knobel F, Guelar A. Adherencia: cómo medirla y mejorarla. En: González-García J, Moreno S, Rubio R, editores. Infección por VIH 1999. Madrid: Ediciones Doyma; 1999: p. 221-246.